Astellas’s Venture Arm Is Focused On Flexibility But Avoiding Hype

VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”  

Greenshoots
Hardiman is seeing 'green shoots of recovery' in the biopharma market • Source: Shutterstock

“We've got geopolitical pressures, macro-economic pressures, interest rates, inflation…” Bradley Hardiman, senior director of business development at Astellas Venture Management, listed the challenges for biopharma going into 2024. “But as an industry, we've always had something that challenges us, and we've always overcome it,” he told In Vivo on the sidelines of the recent BIO-Europe conference in Munich, Germany.

Hardiman was previously an investor at Spex Capital before joining Astellas in April 2022, initially in the company’s internal business...

More from VC Playbook

In Conversation With Foundation Fighting Blindness

 
• By 

Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By 

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By 

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Mixed Bag For Biopharma Funding In 2025: Dispatches From J.P. Morgan, Biotech Showcase

 
• By 

The J.P. Morgan Healthcare Conference and Biotech Showcase revealed what investors are really thinking about the health of the capital markets this year.

More from Growth